Tue, February 17, 2009
Mon, February 16, 2009
Sun, February 15, 2009
Sat, February 14, 2009
Fri, February 13, 2009
Thu, February 12, 2009
Wed, February 11, 2009
Tue, February 10, 2009

Active Biotech: ORAL LAQUINIMOD FOR MULTIPLE SCLEROSIS GRANTED FAST TRACK STATUS BY FDA


  Copy link into your clipboard //science-technology.news-articles.net/content/2 .. -sclerosis-granted-fast-track-status-by-fda.html
  Print publication without navigation Published in Science and Technology on , Last Modified on 2009-02-12 09:03:07 by Market Wire


JERUSALEM and LUND, SWEDEN--(Marketwire - February 12, 2009) - Teva Pharmaceutical Industries Ltd. (NASDAQ: [ TEVA ]) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced that oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS), has received a Fast Track designation from the U.S. Food and Drug Administration (FDA). Teva completed enrollment for the first of its two Phase III clinical trials for laquinimod (ALLEGRO) in November 2008 and is currently enrolling RRMS patients globally for the second Phase III study (BRAVO).

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.


Publication Contributing Sources

Similar Science and Technology Publications